Brandon Scalea

Ibrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.

Dostarlimab (TSR-042), an investigational anti–PD-1 therapy, demonstrated durable responses across subgroups of patients with microsatellite instability–high and microsatellite stable advanced or recurrent endometrial cancer, according to results from the phase I/II GARNET study.

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provides insight into the role of immunotherapy in bladder cancer.

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided CRC and highlights recent research on tumor sidedness and its impact on clinical practice.

Michael J. Overman, MD, discusses the combination regimen of nivolumab and ipilimumab in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Kristen Ciombor, MD, MSCI, discusses the promise of liquid biopsies in the rapidly evolving mCRC paradigm and the potential implications of the COLOMATE trial.

According to Raoul S. Concepcion, MD, FACS, the field of castration-resistant prostate cancer continues to progress with new treatment options; next steps include tailoring these new treatment strategies to individual patients.

Joseph F. Stilwill, MD, shares insight on the benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlighted ongoing research aimed at overcoming acquired resistance.

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflected on progress made in prostate cancer.

Nina Shah, MD, discusses the promise of the CAR T-cell therapy bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma.

Bempegaldesleukin, a novel interleukin-2 therapy, showed promising activity when combined with nivolumab in patients with metastatic urothelial carcinoma who were cisplatin ineligible or refused standard therapy, according to preliminary data from the PIVOT-02 study.

David S. Siegel, MD, PhD, discusses a trial in which patients with multiple myeloma who progressed on lenalidomide were treated with a pomalidomide-based regimen.

Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on CTCs and cfDNA—and highlights ongoing research in the space.

The phase III ICARIA-MM trial has met its primary endpoint of improving progression-free survival with the combination of pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma compared with pomalidomide and dexamethasone alone.

Rogerio Lilenbaum, MD,&nbsp;highlights the current treatment approaches for patients with <em>EGFR</em>-positive NSCLC and sheds light on the potential for immunotherapy in the space.

Matthew S. Davids, MD, MMSc, discusses findings from an updated analysis of the&nbsp;phase III DUO study in patients with CLL.

Updated data from the JULIET trial,&nbsp;which were presented at the 2018 ASH Annual Meeting, underscore the impact of&nbsp;tisagenlecleucel for patients with diffuse large B-cell lymphoma, said&nbsp;Richard T. Maziarz, MD, the trial&#39;s lead investigator.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;discusses recent advances with individualized medicine in CRC, as well as the unmet needs that still exist in this area.

D. Ross Camidge, MD, PhD,&nbsp;discusses the crowded landscape of oncogene-driven non&ndash;small cell lung cancer.

Joaquim Bellmunt, MD, PhD, discusses recent immunotherapy advancements in bladder cancer and what future research will look like.

C. Ola Landgren, MD, PhD,&nbsp;discusses the role of MRD negativity and the emergence of CAR T-cell therapy in multiple myeloma.

Paul R. Eber, MD,&nbsp; discusses how the findings from the phase III CARMENA trial impact mRCC treatment and what challenges remain.<br /> &nbsp;

Danny Rischin, MD,&nbsp;discusses the potential of cemiplimab in patients with cervical cancer. The PD-1 inhibitor cemiplimab demonstrated antitumor activity and a tolerable safety profile as a monotherapy and in combination with&nbsp;hypofractionated radiotherapy for the treatment of&nbsp;patients with metastatic or recurrent cervical cancer.

Cathy Eng, MD, discusses the current paradigm of GI cancers, specifically sharing insight on colorectal cancer and hepatocellular carcinoma.<br /> &nbsp;

In an interview with&nbsp;<em>Targeted Oncology</em>, Jonathon B. Cohen, MD, discussed the evolving treatment landscape of MCL.

Toni K. Choueiri, MD, discusses pivotal phase III findings for the combination of axitinib plus&nbsp;avelumab in previously untreated patients with metastatic renal cell carcinoma.

Chimeric antigen receptor T-cell therapy has generated new excitment in select hematologic malignancies. Despite recent advances, more research is necessary in order to both move these treatments to earlier settings and drive costs down, Brian Till, MD, noted.

Ronald de Wit, MD, PhD, discusses&nbsp;the clinical implications of pembrolizumab in patients with&nbsp;nonmuscle&ndash;invasive bladder cancer.

The treatment landscapes of Hodgkin lymphoma and mantle cell lymphoma have progressed to a more personalized therapeutic approach in clinical practice due to the introduction of the latest novel regimens, according to&nbsp;Chaitra S. Ujjani, MD.

In an interview with <em>Targeted Oncology</em>, Geoffrey Oxnard, MD, discussed the promise of genome-wide sequencing in cfDNA.